Veru Inc. (VERU)

Market Cap	40.75M -21.5%
Revenue (ttm)	n/a
Net Income	-13.61M
EPS	-0.67
Shares Out	17.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,898
Open	2.350
Previous Close	2.320
Day's Range	2.349 - 2.400
52-Week Range	2.050 - 7.330
Beta	-1.16
Analysts	Strong Buy
Price Target	24.50 (+925.11%)
Earnings Date	Aug 10, 2026

About VERU

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly pat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 19, 1990
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: VERU
• Website: https://verupharma.com

Analyst Summary

According to 2 analysts, the average rating for VERU stock is "Strong Buy." The 12-month stock price target is $24.5, which is an increase of 925.11% from the latest price.

Price Target

$24.5

(925.11% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 18, 2026

Data Sources Report a data error